mdxhealth
Jolly Shrivastava is a Bioinformatics Scientist with extensive experience in developing and analyzing pipelines for next-generation sequencing (NGS) and quantitative PCR (qPCR) assays. Currently, Jolly is employed at mdxhealth since October 2023, having previously worked at Fulgent Genetics from December 2020 to October 2023 as a Bioinformatics Scientist II. Prior roles include positions at Biocept, Inc. and ResearchDx, where Jolly focused on identifying SNPs and mutant copies, performing single-cell analysis using various platforms, and maintaining NGS pipelines for variant identification. Jolly earned a Doctor of Philosophy (PhD) in Bioinformatics from the University of California, Riverside, and also holds an education background from California State University, Fullerton.
mdxhealth
Mdxhealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California.